ImmunoIVD specializes in the development of advanced newborn screening kits aimed at the early detection of severe conditions such as Severe Combined Immunodeficiency (SCID), X-Linked Agammaglobulinemia (XLA), and Spinal Muscular Atrophy (SMA). Their innovative platform is designed to streamline the assay process, making it efficient and user-friendly for busy screening laboratories. By utilizing pre-filled plates and minimizing the need for pipetting, ImmunoIVD enhances operational efficiency, enabling DNA analysis from dried blood spot samples to be completed within a three-hour timeframe. This rapid turnaround is crucial for facilitating timely life-saving interventions.

The company prides itself on its collaborative approach, with a dedicated team of scientists providing personalized assistance and swift support to their customers. ImmunoIVD's screening kits are already in use across various European countries, integrated into routine screening programs and pilot projects. This widespread adoption underscores the reliability and effectiveness of their technology in improving newborn health outcomes through early detection of critical health conditions.

Sweden

ImmunoIVD focuses on molecular assays for neonatal screening. The SPOT-it™ kit is CE marked and has been developed to facilitate population-scale screening to detect newborns with SCID, XLA and/or SMA.

The company is built on a strong foundation with more than 30 years experience of successfully running a biotech company, and world renowned researchers within the field of clinical immunology and immunogenetics.  

Early detection increases the chances for children born with SCID, XLA and SMA to live life to its fullest. We believe all children should be given that chance. 

ImmunoIVD

Company Details